2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

IMPROVING VALUE OF CARE IN ONCOLOGY
3. Transparent–the methodology of RLS and the incentives
of every collaborator and contributor will be
visible
4. Independent–the credibility of RLS depends on oncology
peer decision-making and collaboration without
compromise of principles. There will be a firewall
between industry and guideline and standards development
5. Inclusive–ASCO is open to collaborating with any organization,
public or private, that accepts its collaboration
principles. RLS will be accessible and usable
from non-ASCO platforms
6. Streamlined–RLS data collection will be efficient and
not burdensome to providers
7. Sustainable–ASCO will make a substantial investment
in RLS and needs a sustainable economic model. Any
commercialization of RLS will be supported by ASCO’s
educational and quality endeavors
The plan for building the RLS is to begin with small pilot
projects to build the foundation of the system. The foundation
of the RLS is comprised of three key components:
1. Data Governance
2. Data Standards
3. Flexible Technology Platform.
ASCO will convene experts in the area of data governance
to develop a defined set of policies and procedures on how
data are collected, secured, accessed, aggregated, and reported.
The Society will engage experts from government
agencies, law firms, health systems, academic centers, community
practices, and other industries to ensure the RLS is
built with the strongest and most transparent data governance
polices possible. These policies will be maintained by
a board of experts who will be responsible for stewarding
and updating the documents.
Authors’ Disclosures of Potential Conflicts of Interest
Author
Employment or
Leadership
Positions
Consultant or
Advisory Role
Joseph O. Jacobson*
Michael N. Neuss EMeRged Systems
(U), (L)
Robert Hauser Amgen; Novartis
*No relevant relationships to disclose.
1. Institute of Medicine: Crossing the Quality Chasm: A New Health
System for the Twenty-first Century. Washington DC: National Academies
Press, 2001.
2. Mariotto AB, Robin Yabroff K, Shao Y, et al. Projections of the Cost of
Cancer Care in the United States: 2010. J Natl Cancer Inst. 2011;103:117-
128.
3. Smith TJ, Hillner BE. Bending the Cost Curve in Cancer Care. N Engl
J Med. 2011;364:2060-2065.
4. Stegmeier F, Warmuth M, Sellers WR, et al. Targeted Cancer Therapies
in the Twenty-First Century: Lessons From Imatinib. Clin Pharmacol Ther.
2010;87:543-552.
5. Barbash GI, Glied SA. New technology and health care costs-the case of
robot-assisted surgery. N Engl J Med. 2010;363:701-704.
6. Porter ME, Teisberg EO. Redefining health care: Creating value-based
competition on results. Boston, MA: Harvard Business School Press, 2006.
7. Porter ME. What is value in health care? N Engl J Med. 2010;363:2477-
2481.
8. Pollock RE. Value-based health care: The MD Anderson experience. Ann
Surg. 2008;248:510-518.
A second key project in the process is to define data
standards. ASCO will work with and convene panels of
experts to begin to build on work in medical data standards
and enhance the oncology data standards already developed.
For data to be easily aggregated, common definitions are
needed in which all systems report. Developing this data
“ontology” in oncology, will be paramount to the success of
the system.
ASCO will soon be selecting a technology platform on
which to build the RLS. Choosing the correct technology
platform is critical as ASCO develops the RLS. The platform
will need to have the ability to work within the constraints
of data and technology today, but be flexible enough to
adjust to the health information technology systems and
software of the future. Again, ASCO will engage experts in
health information technology, oncology, and developers to
help guide its decisions in this arena. Once the foundation of
the RLS is built, then portals and applications will be built.
ASCO currently envisions having physician portals, clinical
decision support portals, patient portals, and numerous
applications to enhance the quality of oncology care.
Conclusion
ASCO has developed and earned the trust of its members
since 1964 and has a dedicated mission to improve quality
and a history of successful projects and programs. QOPI and
the QOPI Certification Program allow ASCO participants to
measure and improve practice performance, to compare
themselves to their peers, and to guarantee that they adhere
to safe chemotherapy administration practices. To continue
to lead the field, and to respond to the urgent need to
improve the value of cancer care, ASCO is investing in the
development of a comprehensive information technologybased
Rapid Learning System.
Stock
Ownership Honoraria
REFERENCES
Research
Funding
Expert
Testimony
Other
Remuneration
9. Sprandio J. Oncology patient-centered medical home and accountable
cancer care. Community Oncology. 2010;7:565-572.
10. Bach PB, Mirkin JN, Luke JJ. Episode-based payment for cancer care:
A proposed pilot for Medicare. Health Aff (Millwood). 2011;30:500-509.
11. Bohmer RM. The four habits of high-value health care organizations.
N Engl J Med. 2011;365:2045-2047.
12. Landi L, Cappuzzo F. Targeted therapies: Front-line therapy in lung
cancer with mutations in EGFR. Nat Rev Clin Oncol. 2011;8:571-573.
13. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall
survival in patients with advanced non-small-cell lung cancer harbouring
ALK gene rearrangement: A retrospective analysis. Lancet Oncol. 2011;12:
1004-1012.
14. Sox HC. Medical Professionalism and the Parable of the Craft Guilds.
Ann Intern Med. 2007;147:809-810.
15. Jacobson JO. Multidisciplinary Cancer Management: A Systems-Based
Approach to Deliver Complex Care. J Oncol Pract. 2010;6:274-275.
16. Auerbach AD, Landefeld CS, Shojania KG. The Tension between
Needing to Improve Care and Knowing How to Do It. N Engl J Med.
2007;357:608-613.
e75